Research programme: interferon regulatory factor 3 modulator therapeutics - Jnana Therapeutics
Latest Information Update: 03 Oct 2024
Price :
$50 *
At a glance
- Originator Jnana Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Interferon regulatory factor 3 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 23 Sep 2024 Jnana Therapeutics has been acquired by Otsuka Pharmaceutical
- 25 Nov 2022 Early research in Immunological disorders in USA (unspecified route) prior to November 2022 (Jnana Therapeutics pipeline, November 2022)